医学捌号楼
 
Web www.med8th.com
首页 | 医疗资讯 | 人与医学 | 阅览室 | 诺贝尔奖 | 专业资源 | 院士录 | 中医
医学捌号楼・皮肤科・

莱克兰地区癌症中心获得Rosetta Resolver基因表达数据分析系统使用授权


管理员  | 2013-04-11 13:39:05

(BW)(WA-ROSETTA-BIOSOFTWARE)(MRK) 莱克兰地区癌症中心获得Rosetta Resolver基因表达数据分析系统使用授权

美国商业新闻2006年2月6日佛罗里达州莱克兰和西雅图消息――

莱克兰地区癌症中心(Lakeland Regional Cancer Center)和Rosetta生物软件公司(Rosetta Biosoftware)今天宣布,莱克兰地区癌症中心获得Rosetta Resolver?系统使用授权,用于研究微阵列(microarray)在癌症分期中的临床价值。“癌症分期”是指诊断时描述某种癌症严重程度的过程。

Rosetta生物软件公司总裁兼总经理Yelena Shevelenko说,“Resolver系统是一套可扩展的全面信息学解决方案,能够提供基因表达数据的分析和管理,满足癌症研究中发现生物标志的需求。我们很高兴能为莱克兰地区癌症中心提供工具,加快研究步伐,简化分子级预后。”

莱克兰地区癌症中心分子分期实验室主任、基础科学与应用研究副主任Steven C. Shivers博士说,“在我们的分子分期实验室,我们测试各类分子阵列对于癌症分期的临床价值。Resolver系统将是研究寡核苷酸微阵列临床价值的重要工具。Resolver系统的可靠性和灵活性将为各类癌症分期应用带来好处,包括发现预后和/或治疗响应性(therapy-responsive)生物标志。”

Rosetta Resolver系统由Rosetta生物软件公司开发并提供支持,由Agilent Technologies公司独家分销。

关于莱克兰地区癌症中心

莱克兰地区癌症中心(Lakeland Regional Cancer Center)不断寻求癌症的治愈方法,并通过预防、早期检查、治疗、研究,致力于提供优异的癌症康复救治。莱克兰地区癌症中心是社区肿瘤学资源机构(community oncology resource),在癌症研究和患者救治方面处于国际领先地位。通过在分子化学实验室开展研究,积极参与临床实验治疗项目,与各大癌症中心联网,莱克兰地区癌症中心以最新的治疗技术走在最前沿。每天,全世界的癌症病人都从他们坚持不懈、孜孜以求的研究和他们许诺的希望中受益。莱克兰地区癌症中心真正把患者放在重要位置,提供手术肿瘤学、放射肿瘤学、内科肿瘤学、血液学和泌尿学领域医术精湛、医德高尚的医生。

关于Rosetta Resolver系统

Rosetta Resolver系统是一套大容量数据存储、检索和分析解决方案,用于基因表达数据处理。生命科学研究机构如需评估化合物的特异性或毒性,辨识新基因或治疗性目标或比较、分析大型基因表达谱数据库,该系统是最理想的产品。Rosetta Resolver系统将灵活性、易用性和高性能算法结合,能够生成一套全面的解决方案,用于基因表达数据的快速分析。Rosetta Resolver系统可接受并分析多种基因表达谱格式的数据(包括Agilent DNA微阵列),并应用Rosetta生物软件公司专有的误差模型,为系统中每个基因表达测量数据生成高质量统计报告。Rosetta Resolver系统分析工具将自动处理此类统计信息,从而获得最优结果。

众多生命科学机构已经获得了Rosetta Resolver系统的授权,其中包括Aventis Pharmaceuticals、Bristol-Myers Squibb、GlaxoSmithKline和默克公司在内的全球一流的制药公司以及像哈佛大学基因组研究中心及加州理工学院这样的一流学术机构。了解关于Rosetta Resolver系统的更多信息,请访问Rosetta Biosoftware网站: http://www.rosettabio.com

关于Rosetta生物软件公司

Rosetta生物软件公司(Rosetta Biosoftware)为生命科学研究提供信息解决方案,是该领域的领先供应商。其全面的软件解决方案,包括Rosetta Resolver和Rosetta Elucidator系统,能够为生命科学家提供技术先进、使用方便、可扩展的分析平台,从而促进发现研究。Rosetta生物软件公司是默克公司(Merck & Co., Inc.,纽约证券交易所:MRK)旗下企业Rosetta Inpharmatics有限责任公司下属的业务部门。欲了解关于Rosetta生物软件公司的更多信息,请访问: http://www.rosettabio.com

前瞻性表述

本新闻发布稿含有《1995年私人证券诉讼改革法案》中定义的“前瞻性表述”。这些表述涉及风险和不确定因素,可能导致实际结果与表述内容产生重大差异。前瞻性表述可能包含有关产品开发、产品潜力或财务业绩的表述。前瞻性表述都无法得到保障,实际结果可能与表述中预期产生重大差异。无论是因为出现新的信息,未来发生某事件或其它情形,Rosetta Inpharmatics公司和默克公司均不承担公开更新任何前瞻性表述的任何责任。本新闻发布稿中的前瞻性表述应结合可能影响默克公司业务的诸多不确定因素进行评价;这些不确定因素之中包括但不限于,Rosetta Inpharmatics公司的技术平台在药物发现项目中应用的程度;与Rosetta Inpharmatics公司技术的市场接受程度相关的不确定因素;与现有技术展开竞争的能力;默克公司10-K表(2004年12月31日结束的财政年度)第1部分(Item 1)警告性声明中提及的因素以及公司10-Q表和8-K表(如有的话)季度报告中包含的参考内容中提及的因素。

Rosetta Resolver和Rosetta Elucidator是Rosetta Inpharmatics有限责任公司在美国的注册商标。

联系方式:与Rosetta生物软件公司联系: Lisa Owen,206-926-1236 或者 与莱克兰地区癌症中心联系: 863-603-6565

(BW)(WA-ROSETTA-BIOSOFTWARE)(MRK) Lakeland Regional Cancer Center Licenses the Rosetta Resolver Expression Data Analysis System

LAKELAND, Fla., and SEATTLE--(BUSINESS WIRE)--Feb. 6, 2006--

Lakeland Regional Cancer Center and Rosetta Biosoftware announced today that Lakeland Regional Cancer Center licensed the Rosetta Resolver? system to investigate the clinical value of microarrays for assisting in cancer staging, the process of describing the severity of a cancer at the time of diagnosis.

"The Resolver system is a comprehensive and scalable informatics solution that addresses the gene expression data analysis and management needs for biomarker discovery in cancer research," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. "We are pleased to provide Lakeland Regional Cancer Center with tools to advance research in facilitating prognosis on a molecular level."

"In our Molecular Staging Laboratory, we test the clinical value of various molecular assays for cancer staging," said Steven C. Shivers, Ph.D., associate director for basic science and translational research and director of the Molecular Staging Laboratory at Lakeland Regional Cancer Center. "The Resolver system will be an important tool for investigating the clinical value of oligonucleotide microarrays. The reliability and flexibility of the Resolver system will benefit various cancer staging applications, including the discovery of prognostic and/or therapy-responsive biomarkers."

The Rosetta Resolver system is developed and supported by Rosetta Biosoftware, and is distributed exclusively by Agilent Technologies.

About Lakeland Regional Cancer Center

Lakeland Regional Cancer Center is committed to delivering exceptional cancer care through prevention, early detection, treatment, research, and the relentless pursuit of a cure. Lakeland Regional Cancer Center is a community oncology resource and proudly claims an international leadership position in cancer research and patient care. By conducting research in molecular chemistry laboratories, actively participating in clinical trial protocols, and networking with major cancer centers, Lakeland Regional Cancer Center stands at the forefront with the latest treatment advances. Every day, cancer patients throughout the world benefit from their unwavering commitment to research and its promise of hope. Truly patient-focused, Lakeland Regional Cancer Center provides highly skilled and compassionate physicians who specialize in Surgical Oncology, Radiation Oncology, Medical Oncology and Hematology, and Urology.

About the Rosetta Resolver System

The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats, including Agilent DNA microarrays, and applies Rosetta Biosoftware's proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results.

Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Aventis Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline and Merck & Co., Inc., as well as premier academic institutions such as the Harvard University Center for Genomics Research and the California Institute of Technology. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com.

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver and Rosetta Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE:MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2004, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Rosetta Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.

CONTACT: For Rosetta Biosoftware Lisa Owen, 206-926-1236 or For Lakeland Regional Cancer Center 863-603-6565

相关内容
莱克兰地区癌症中心获得Rosetta Resolver基因表达数据分析系统使用授权
/yiliaozixun/jichuyixue/234.html
更新日期:2013-04-11 13:39:05
心脏病发作易致命谨记信号
妇女反复肠胃不适警惕卵巢癌
外来医械的“死角”
《上海市基本医疗保险和工伤保险药品目录(2005年版)》――9调节免疫功能药
易瑞沙被消费者要求禁售
以宪法还他们平等
注射的滥用、危险与安全措施
为我国中医药业进一言
中医的“系统”是一个未经实证也难以否证的系统
没管好食品含盐量FDA被起诉
中草药没有副作用吗? 谈“中国草药肾病变”
“为什么没有人告诉我?”��龙胆泻肝丸导致肾损害采访手记
我想问问包皮过长的哥们几天清洗一次?
乳腺癌疫苗就要临床试验了
“乙肝”问题的社会学解读
高耀洁:欲罢不能
排毒养颜,还有许多话要说
VX-680治疗白血病临床研究启动
糖尿病人饭后有八“戒”
儿童气促及哮喘诊断和治疗
药物依赖,隐瘾作痛
中医存废困境:西医改造中医将致中医灭亡
包皮环切术可提供65%的保护免于艾滋病感染
男性环割包皮能否预防艾滋病有待研究
我国学者在艾滋病患者房水中首次找到HIV病毒载量
“乙肝歧视”所引发的人权思考
药物责任与消费者保护
打破“艾滋病长城”里的沉默
质疑安利营养品是个骗局
医疗始于对生命的尊重:『杀人医师』案例分析
非正常医疗现象不断蔓延
「卫生医疗体系优先级制定」之研究
江苏省城乡医疗卫生的不平等性研究
Wonca强调家庭医生治疗呼吸系统疾病患者的全球中心任务
印度特产:乙肝疫苗28美分一针
招聘公务员体检标准增加DNA检测是乙肝歧视的升级!
山东省立医院引进全数字乳腺癌检查系统
中医药产业沉默吞下“马兜铃酸苦果”
台湾锰中毒劳工要求劳工保险全面给付医疗费
英国护士不愿推迟退休年龄
北医三院成功为一患者彻底切除寰枢椎区域内肿瘤
中草药的五大危险因素
莱克兰地区癌症中心获得Rosetta Resolver基因表达数据分析系统使用授权
淘大花园爆发严重急性呼吸系统综合症事件主要调查结果
伟哥可能引发永久性视力损害
排毒养颜胶囊欲盖弥彰
心脑血管科
H7N9未被阻断人或被感染
国家突发公共卫生事件应急预案
中国护理事业发展规划纲要(2005―2010年)